146 related articles for article (PubMed ID: 35580293)
1. Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.
Long AH; Morgenstern DA; Leruste A; Bourdeaut F; Davis KL
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-14. PubMed ID: 35580293
[TBL] [Abstract][Full Text] [Related]
2. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
[TBL] [Abstract][Full Text] [Related]
3. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.
Paul S; Zahurak M; Luznik L; Ambinder RF; Fuchs EJ; Bolaños-Meade J; Wagner-Johnston N; Swinnen LJ; Schoch L; Varadhan R; Jones RJ; Gladstone DE
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1679-1688. PubMed ID: 32592857
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.
Fang W; Zhao S; Zhang Y; Ma Y; Zhao H; Zhang L
Oncologist; 2019 Feb; 24(Suppl 1):S11-S20. PubMed ID: 30819827
[TBL] [Abstract][Full Text] [Related]
6. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
7. The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy.
Kwon M; Jung H; Nam GH; Kim IS
J Control Release; 2021 Mar; 331():321-334. PubMed ID: 33434599
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape.
Ebrahimi S; Habibzadeh A; Khojasteh-Kaffash S; Valizadeh P; Samieefar N; Rezaei N
Crit Rev Oncol Hematol; 2024 Jan; 193():104225. PubMed ID: 38049077
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials.
Akhbariyoon H; Azizpour Y; Esfahani MF; Firoozabad MSM; Rad MR; Esfahani KS; Khoshavi N; Karimi N; Shirinisaz A; Abedi F; Rad MR; Sharifi P
Clin Immunol; 2021 Nov; 232():108873. PubMed ID: 34688855
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment.
Liao JY; Zhang S
Front Oncol; 2021; 11():663264. PubMed ID: 34123821
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
13. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
14. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
15. The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors.
Mittra A; Takebe N; Florou V; Chen AP; Naqash AR
Hum Vaccin Immunother; 2021 Jul; 17(7):1935-1939. PubMed ID: 33325769
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
[TBL] [Abstract][Full Text] [Related]
18. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Bagchi S; Yuan R; Engleman EG
Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
